Altimmune reports Q4 2021 net loss of $23.9M ($0.57/share); cash $190.3M; pemvidutide trials on track

Altimmune, Inc.

Net loss $23.9M ($0.57 per share) vs $10.6M ($0.29) in Q4 2020; R&D expense doubled to $20.2M on pemvidutide development.
Cash, equivalents and short-term investments of $190.3M at Dec 31, 2021; revenue $3.3M vs $2.3M.
Pemvidutide Phase 1b NAFLD trial >90% enrolled; topline data expected Q3 2022.
Phase 2 MOMENTUM obesity trial (48 wks) initiation expected Q1 2022; interim data at 24 wks in Q4 2022.
HepTcell Phase 2 chronic hepatitis B trial enrollment ongoing; readout expected H1 2023.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.